Literature DB >> 26277400

GnRH-(1-5) activates matrix metallopeptidase-9 to release epidermal growth factor and promote cellular invasion.

Madelaine Cho-Clark1, Darwin O Larco1, Brian R Zahn1, Shaila K Mani2, T John Wu3.   

Abstract

In the extracellular space, the gonadotropin-releasing hormone (GnRH) is metabolized by the zinc metalloendopeptidase EC3.4.24.15 (EP24.15) to form the pentapeptide, GnRH-(1-5). GnRH-(1-5) diverges in function and mechanism of action from GnRH in the brain and periphery. GnRH-(1-5) acts on the orphan G protein-coupled receptor 101 (GPR101) to sequentially stimulate epidermal growth factor (EGF) release, phosphorylate the EGF receptor (EGFR), and facilitate cellular migration. These GnRH-(1-5) actions are dependent on matrix metallopeptidase (MMP) activity. Here, we demonstrated that these GnRH-(1-5) effects are dependent on increased MMP-9 enzymatic activity in the Ishikawa and ECC-1 cell lines. Furthermore, the effects of GnRH-(1-5) mediated by GPR101 and the subsequent increase in MMP-9 enzymatic activity lead to an increase in cellular invasion. These results suggest that GnRH-(1-5) and GPR101 regulation of MMP-9 may have physiological relevance in the metastatic potential of endometrial cancer cells. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Cancer; Cell invasion; Endometrial; Epidermal growth factor receptor (EGFR); G protein-coupled receptor (GPCR); GnRH; Matrix metalloproteinase (MMP); Orphan receptor

Mesh:

Substances:

Year:  2015        PMID: 26277400     DOI: 10.1016/j.mce.2015.08.010

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

Review 1.  Peripheral and Central Mechanisms Involved in the Hormonal Control of Male and Female Reproduction.

Authors:  L M Rudolph; G E Bentley; R S Calandra; A H Paredes; M Tesone; T J Wu; P E Micevych
Journal:  J Neuroendocrinol       Date:  2016-07       Impact factor: 3.627

2.  Screening for GPR101 defects in pediatric pituitary corticotropinomas.

Authors:  Giampaolo Trivellin; Ricardo R Correa; Maria Batsis; Fabio R Faucz; Prashant Chittiboina; Ivana Bjelobaba; Darwin O Larco; Martha Quezado; Adrian F Daly; Stanko S Stojilkovic; T John Wu; Albert Beckers; Maya Lodish; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2016-06-01       Impact factor: 5.678

3.  GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency.

Authors:  F Castinetti; A F Daly; C A Stratakis; J-H Caberg; E Castermans; G Trivellin; L Rostomyan; A Saveanu; N Jullien; R Reynaud; A Barlier; V Bours; T Brue; A Beckers
Journal:  Horm Metab Res       Date:  2016-01-21       Impact factor: 2.936

Review 4.  Neuropeptide and steroid hormone mediators of neuroendocrine regulation.

Authors:  A L Heck; C C Crestani; A Fernández-Guasti; D O Larco; A Mayerhofer; C E Roselli
Journal:  J Neuroendocrinol       Date:  2018-08-07       Impact factor: 3.627

5.  Regulation of Gonadotropin-Releasing Hormone-(1-5) Signaling Genes by Estradiol Is Age Dependent.

Authors:  Bradly M Bauman; Weiling Yin; Andrea C Gore; T John Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-27       Impact factor: 5.555

6.  Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer.

Authors:  Aneta Cymbaluk-Płoska; Anita Chudecka-Głaz; Ewa Pius-Sadowska; Agnieszka Sompolska-Rzechuła; Karolina Chudecka; Michał Bulsa; Bogusław Machaliński; Janusz Menkiszak
Journal:  Dis Markers       Date:  2017-09-27       Impact factor: 3.434

7.  Comparative transcriptome analysis between patient and endometrial cancer cell lines to determine common signaling pathways and markers linked to cancer progression.

Authors:  Madelaine J Cho-Clark; Gauthaman Sukumar; Newton Medeiros Vidal; Sorana Raiciulescu; Mario G Oyola; Cara Olsen; Leonardo Mariño-Ramírez; Clifton L Dalgard; T John Wu
Journal:  Oncotarget       Date:  2021-12-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.